Khiron Receives First Medical Cannabis Prescriptions for UK Patients Participating in Project Twenty21

Nachrichtenquelle: PR Newswire (engl.)
06.05.2020, 06:01  |  240   |   |   

Khiron is the exclusive Latin American supplier to Project Twenty21, a leading UK registry study enrolling up to 20,000 patients by the end of 2021, to create the largest body of evidence in Europe for the effectiveness and tolerability of medical cannabis

  • First import of EU GMP medical cannabis products is complete

  • Khiron branded products available to participating UK doctors, with first prescriptions now received

  • Khiron has secured a strategic partnership with an EU GMP fulfilment partner which can deliver patient prescriptions to their homes

  • UK medical cannabis clinics and doctors have received regulatory approval to conduct teleconsultations with patients, a new milestone in opening up patient access

  • Approximately 1.4m people in Great Britain are using "street cannabis" to treat medically diagnosed, chronic health conditions (source: YouGov)

  • By 2024, the UK medical cannabis market is predicted to be worth nearly £1bn, servicing nearly 340,000 active patients (source: Prohibition Partners)

TORONTO, May 6, 2020 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQX: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, today announced the receipt of its first medical cannabis prescriptions for patients participating in Project Twenty21 in the United Kingdom (UK). Khiron branded EU GMP medical cannabis is now available for prescription from doctors and clinics participating in Project Twenty21, Europe's largest study of the effectiveness and tolerability of medical cannabis.

Khiron Life Sciences Corp. (CNW Group/Khiron Life Sciences Corp.)

Khiron has been actively preparing to supply Project Twenty21 since first announcing its participation in November 2019. The supply of EU GMP medical cannabis is fully supported by the Company's global medical education team, led by Dr. Maria Fernanda Arboleda, International Director for Medical Services. Khiron will leverage educational materials and key learnings from the Company's Colombian cannabis experience in making therapeutic recommendations for Project Twenty21.

Leading the project, Professor David Nutt from the UK's leading independent scientific body Drug Science commented: "Khiron's assistance in delivering Project Twenty21 will expand the formulary significantly. Our shared vision, accelerating access of medical cannabis to patients who need it the most, will be greatly enhanced by the support provided by the Khiron team."

Seite 1 von 4
#Khiron Life Sciences Aktie jetzt ab 0€ handeln - auf

Diesen Artikel teilen

Diskussion: KHRN - mit scharrenden Hufen zum Sprung in andere Dimension bereit!
Mehr zum Thema
Klicken Sie auf eines der Themen und seien Sie stets dazu informiert. Mehr Informationen hier.

0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren



Meistgelesene Nachrichten des Autors


Diskussionen zu den Werten